




OmniAb, Inc.
Investor & Analyst Day
Nasdaq: OABI

*October 6, 2026
8:00 a.m. PT
Emeryville, California*



Disclaimer

We caution you that this presentation contains forward-looking statements.

All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance for 2026, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our technology platform and other technologies, our or our partners' expectations regarding the addressable markets for our technologies or their product candidates, as applicable, including the growth rate of the markets in which we operate, our competitive advantage and the growth prospects of our business, the scalability of our business, our ability to leverage the growth of our business and to do so efficiently, the timing of the initiation or completion of preclinical studies and clinical trials by our partners, expectations regarding potential safety and therapeutic benefits of our partners' product candidates, whether they could be first-in-class or best-in-class, product approvals and potential for future revenue growth, launches by our partners and the timing thereof, the anticipated introduction of new technologies and innovations and enhancement of our technology stack and partners' experiences, the continued innovation around and the expected performance of our technologies and the opportunities and earnings and cash flow accretion they may create, including xPloration, OmnidAb, OmniUltra and OmniTides, the ability to add new partners and programs, the scientific presentations and clinical and regulatory events of our partners and the timing thereof, the potential for and timing of receipt of milestones and royalties under our license agreements with partners, and the potential predictability and durability of revenue streams and cash flows, and our 2026 financial guidance, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain, risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; risks associated with quality and timing in manufacturing our xPloration instruments and related consumables and our reliance on a limited number of third-party manufacturers and suppliers; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; government healthcare reform, legislative measures and regulatory developments in the United States and foreign countries; unstable market and economic conditions, may have serious adverse consequences on our business, financial condition and stock price; we may use our capital resources sooner than we expect; we may not achieve our financial guidance; and other risks described in our press releases and filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Information regarding partnered products and programs comes from reports or information publicly released by our partners and have not been independently verified by OmniAb. For our definitions of "active partners," "active programs," "active clinical programs and approved products" and "approved products", see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 4, 2026.

This presentation also contains estimates and other statistical data made by independent parties and by us and/or our partners relating to market size and growth and other data about the antibody industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Non-GAAP Financial Measures:

This presentation contains non-GAAP financial measures, Cash Costs and Operating Expense, Cash R&D Expense and Cash G&A Expense. We believe these financial measures provide useful information to investors with which to analyze our operating trends and performance. However, non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. See more information on GAAP to non-GAAP financial measures provided in our most recent earnings press release, which is available in the Investors section of our website at investors.omniab.com.



Welcome

Matt Foehr
CEO

Today's Agenda

Topics	Slides
Opening Remarks & Business Overview - Matt Foehr	6 – 21
Licensing - Todd Pettingill	22 – 25
Transgenic Chicken Advantage - Bill Harriman	26 - 31
OmniTides™ Platform - Yasmina Abdiche & Brian McGuinness	32 – 41
xPloration® Platform - Amechi Nwachuku	42 – 58
Enhancing Discovery with AI - Bob Chen	59 - 63
Finance / Wrap Up - Kurt Gustafson	64 - 68

Q&A, followed by lab tours with xPloration demonstrations

Today's Presenters



Matt Foehr
CEO



Todd Pettingill
VP
Business Development &
Strategy



Bill Harriman, Ph.D.
SVP
Discovery Partnership Management &
Technology Development



Yasmina Abdiche, Ph.D.
SVP
Exploratory Research &
Advanced Characterization



Brian McGuinness
Senior Director
Business Development



Amechi Nwachuku
COO



Bob Chen, Ph.D.
SVP
Discovery Systems



Kurt Gustafson
CFO

Mission

Our mission is to enable the rapid development of innovative therapeutics by **pushing the frontiers of drug discovery technologies.**

OmniAb's Business

WE LICENSE PROPRIETARY DISCOVERY TECHNOLOGY TO THE BIOPHARMA INDUSTRY

DIFFERENTIATED TECHNOLOGY PLATFORMS CREATE LICENSING OPPORTUNITIES

Proprietary Transgenic Animals

Create custom *in vivo* libraries for both antibody and peptide discovery

Novel Screening Technologies

xPloration® platform and ion channel screening technologies expand our reach and drive partnerships

BI and AI Powered Discovery

Partners access the Biological Intelligence™ (BI) built into our transgenic animals combined with OmniDeep®, our AI-powered platform, to generate therapeutic candidates

BUSINESS WITH SCALE, LEVERAGABILITY AND MULTIPLE REVENUE STREAMS

110

Active Partners
Majority of Top 10
pharma companies

425

Active Programs
34 clinical programs
and approved products

\$3B+

**Contracted
Milestones**
~\$340M associated with
clinical-stage programs

3.4%

**Average Royalty Rate
Across Portfolio**
>98% of programs have
downstream economics

xPloration®

**Poised for Growth with
Multiple Revenue Streams**
Broad potential in >\$500M market

OmniAb's Pillars of Value

OmniAb is well-positioned to deliver for our stakeholders,
with highly differentiated technologies and multiple ways to efficiently drive value

Pipeline & Partnerships

Substantial contracted downstream milestones & royalties from growing portfolio of potential best-in-class/first-in-class programs

Our broad and growing base of partnerships provides unique vantage point on the industry, and informs our priorities

Discovery Technologies

Expanding suite of innovative technologies that continue to drive partnering and program additions

Chicken-based technologies driving new partnerships and creating new avenues for value creation

xPloration Platform

Differentiated instrument platform creates opportunity to expand our reach

Adds durable and meaningful revenue streams

Synergistic with, and complementary to, existing discovery technology license offerings and business revenue model

The Value of Royalties on Therapeutics



Predictable & Recurring Cash Flows

Pharmaceutical royalties entitle the holder to a percentage of future product sales. For approved drugs with established market adoption, royalty payments can provide highly visible, recurring revenue streams over many years.



Limited Operating & Expense Risks

Royalty owners participate in product success without funding ongoing operations, and don't bear the costs of: clinical trials, manufacturing, sales and marketing, regulatory reviews and compliance



Broad Exposure to Healthcare Market Growth

As populations age and healthcare spending increases globally, successful therapies can experience sustained growth in patient demand and revenue. Because performance is driven primarily by medical outcomes and patent protection, royalties are a financial asset that are more insulated from broader economic cycles than typical financial instruments.



Portfolio Diversification

Broadly applicable. Novel technologies can build a diversified mix of royalty-bearing programs.



Strong Intellectual Property Protection

Drug royalties are typically supported by patents, regulatory exclusivities and/or proprietary manufacturing (or other) know-how. These protections can create significant barriers to competition, allowing innovative therapies to generate premium pricing and durable cash flows over the life of a product.

The Intellectual Property Advantage at OmniAb

PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL


Over 350 technology patents issued worldwide

We maintain a broad intellectual property estate with multiple long duration patent families covering key elements of our technology platform

Approaching 120 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with expiries up to 2046


Licenses are structured so that royalties are linked to the patents for the molecules discovered from our technologies, thereby creating a lengthy coverage tail

Antibody Patent Applications
Filed by Partners



OmniAb Technologies

INNOVATION THAT ENABLES THE DISCOVERY OF NEXT GENERATION THERAPEUTICS



OmniDeep

Suite of *in silico* tools for discovery that are woven throughout our various technologies and capabilities. Includes structural modeling, large multi-species antibody databases, molecular dynamics simulations, AI, machine and deep learning sequence models, and more

OmniAb

The Role of Ion Channels in Health and Disease⁽¹⁾

THERAPEUTIC TARGETS WITH HIGH UNMET MEDICAL NEED

“ I think that ion channels are the most important single class of proteins that exist in the human body, or any body for that matter. ”

– **Clay Armstrong, M.D.**
Albert Lasker Award Interview

Ion channels play an important role in regulating a number of critical biological processes




Heartbeat



Movement



Vision



Hearing



Touch



Smell

Ion channels represent one of the largest drug target classes with many new opportunities for novel therapeutics in areas like pain, epilepsies, arrhythmias and immune disorders


(1) Content adapted from www.ionchannellibrary.com/fundamentals/why-we-should-care-about-ion-channels

- We believe we have developed an industry-leading platform for ion channel drug discovery
- We partner with big pharma players who are interested in pursuing ion channel targets, and want access to our discovery technologies, cell lines, custom reagents and high-throughput screening capabilities specific to ion channels
 - Hundreds of proprietary cell lines and functional assays that enable discovery for most ion channel targets
- License agreements typically include larger license and service fees, including time and pass-through costs, in addition to milestones and royalties




Active Partners


Number of Active Partners⁽¹⁾⁽²⁾



Partner Type



Partner Location⁽³⁾



- 8 of the 10 largest global pharma companies are Active Partners⁽⁴⁾
- Our discovery partnership model provides unique vantage point on industry and informs our innovation and priorities

(1) See our SEC filings for Active Partners definition


(2) Values shown net of attrition

(3) Partner location is based on partner headquarters


(4) Top-10 largest global pharma companies based on 2025 reported sales

Active Programs


Number of Active Programs⁽¹⁾



Over \$3 Billion of Milestone(s) (by Type⁽²⁾)



Distribution of Contracted Royalty Rates (by Program⁽²⁾)




- >98% of our Active Programs have contracted future economics to OmniAb
- Over \$3 billion in total contracted potential milestones⁽²⁾
- Average royalty rate of ~3.4% across portfolio⁽²⁾

(1) See our SEC filings for Active Programs definition


(2) Excludes prepaid licenses and grandfathered licenses, all Ion Channel programs, and programs from Academic Partner/Revenue Share licenses where the economics to OmniAb will be linked to the future transaction with the developmental/commercial entity. For programs with tiered royalties, the royalty rate is calculated as a blended royalty assuming \$1.3B sales level.

Active Clinical Programs and Approved Products


Number of
Active Clinical Programs
and Approved Products⁽¹⁾⁽²⁾



Source Technology



Therapy Area of
Clinical & Commercial Programs



- 34 active clinical programs and approved products, with increasing diverse therapy area distribution
- Active clinical programs have ~\$340 million in remaining potential milestones to OmniAb


(1) See our SEC filings for Active Clinical Programs and Approved Products definition

(2) Values shown net of attrition

Clinical and Commercial-Stage Partner Pipeline⁽¹⁾⁽²⁾ AS OF 6/30/2026

17

ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN



(1) Program placement is based on most advanced status in any geography, market, or indication

(2) Figure excludes any Clinical and Commercial-Stage Active Partner programs that do not have future or remaining economics to OmniAb, e.g., Teclistamab (TECVAYL[®]), Tiragolumab, Etentamig (ABBV-383), Surovatamig (AZD0486), NTB-928 (also known as TNB-298)

(3) Arcus Biosciences evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio (see www.arcus.com)

(4) Ramantamig is also referred to as JNJ-79635322 by Johnson & Johnson Innovative Medicines, reference J&J company disclosures and clinicaltrials.gov; Precentabart tocentecan is also referred to as M9140 by Merck KGaA; IMVT-1402 is also referred to as Imeroprubart by Hanall Biopharma

(5) Program derived from OmnidAb[®] (single domain Chicken technology) or from OmniChicken[®]

Select Late-Stage Partner Programs

MULTIPLE ROYALTY-BEARING PROGRAMS, EACH DESCRIBED AS "PIPELINE-IN-A-PRODUCT" PROGRAMS, ALSO WITH FIRST-IN-CLASS OR BEST-IN-CLASS POTENTIAL

Program (target)	Partner(s)	Stage of Development	Potential First Indication(s) (est. addressable patient population)	Potential Added Indications (est. addressable patient population)
IMVT-1402 (imeroprubart) FcRn	 IMMUNOVANT  HANALL BIOPHARMA	Phase 3	Graves' Disease (300,000 ⁽¹⁾) Myasthenia Gravis (20,000 - 35,000 ⁽¹⁾)	D2T Rheumatoid Arthritis (85,000 ⁽¹⁾) Sjögren's Disease (90,000 ⁽¹⁾) CIDP (16,000 - 58,000 ⁽¹⁾)
Precentabart tocentecan CEACAM-5 ADC	 MERCK	Phase 3	Metastatic Colorectal Cancer (2,000,000 ⁽²⁾)	NSCLC (400,000 ⁽⁴⁾) Pancreatic Ductal Cancer (280,000 ⁽⁵⁾)
TEV-'408 IL-15	 teva	Phase 2b	Vitiligo (4,100,000 ⁽³⁾) Celiac (1,600,000 ⁽³⁾)	Eosinophilic Esophagitis (600,000 ⁽³⁾) Alopecia Areata (2,100,000 ⁽³⁾) Atopic Dermatitis (23,900,000 ⁽³⁾)

(1) Numbers for US only reported by Immunovant in September 2026 (<https://www.immunovant.com/investors/news-events/presentations>)

(2) Number reported by EMD Serono in May 2026 (<https://www.emdserono.com/us-en/company/news/press-releases/phase-three-proceeds-study-investigates-antibody-drug-conjugate-in-colorectal-cancer-05-21-2026.html>)

(3) Numbers reported by Teva in September 2026 (https://s24.q4cdn.com/720828402/files/content_files/Presentation-of-Phase-2a-TLR-in-Celiac-for-TEV-408-Anti-IL-15-For-Website.pdf)


(4) Reference World Health Organization (<https://gco.iarc.who.int/today/en/fact-sheets-cancers/15/trachea-bronchus-and-lung>), Alduais et al. Medicine (2023); Hsu et al. JTO Clin Res Rep. (2025)

(5) Reference World Health Organization (<https://gco.iarc.who.int/today/en/fact-sheets-cancers/13/pancreas>); Park et al. JAMA (2021); Wainberg et al. Ann Onc 2026


Partner Commitment to our Programs

MILESTONE AND ROYALTY BEARING PROGRAMS FUNDED BY OUR PARTNERS

Clinical Trial Starts⁽¹⁾



Planned or Enrolled Patients⁽¹⁾




We estimate our clinical-stage partners have committed to spend more than \$2.4 Billion advancing programs through the clinic that leverage our technologies⁽²⁾

(1) Reference Clinicaltrials.gov

(2) Based on cost per patient build up of \$20,000 per phase 1 patient, \$35,000 per phase 2 patient, \$75,000 per phase 3 patient. Source: <https://novapharmanews.com/us/articles/fda-clinical-trial-cost-analysis-phase1-3-2024>

Select Partner Clinical Read-Out Summary⁽¹⁾

BASED ON CLINICALTRIALS.GOV DISCLOSURES



Color indicates most advanced phase of partner program: Phase 3; Phase 2; Phase 1.

A substantial number of trials are reading out over the next 15 months

(1) Placement on graphic based on estimated primary completion date on clinicaltrials.gov

Highly Leverageable Business, Built for Value-Creation

OUR EXPECTATIONS FOR THE BUSINESS IN THE SHORT-, MID- AND LONG-TERM

Short-Term

next two years

- Existing portfolio positioned to drive growth and major partner news flow
- Milestones from late-stage assets realized
- Potential IMVT-1402 launch
- xPloration foundation, building momentum

Mid-Term

2029 through 2034

- Business evolves and grows, with an increasingly diverse revenue mix and multiple assets launching
- Existing portfolio has potential for multiple major new product launches
- Continue leveraging vantage point in industry to inform technology and workflow expansions

Long-Term

2034 and beyond

- Potential for launch of additional major new drugs from portfolio
- xPloration install base greatly expanded, producing recurring revenue
- Continued robust, efficient and increasingly diversified partnering business model

Controlled expense structure continues to demonstrate the efficiencies and the power of our business platform



Licensing

Todd Pettingill

VP, Business Development & Strategy

Industry Trends Favor OmniAb's Platforms and Position



Biologics Outperform Small Molecules in Clinical Success

Biologics have succeeded in the clinic roughly 60% more often than small molecules, underscoring the value of OmniAb's biologic platforms⁽¹⁾. Also, streamlined non-clinical requirements and expedited review programs are favorable



New Targets Have the Potential to Reshape the Industry

As existing targets grow more crowded⁽²⁾, a broad new range of targets is being unveiled⁽³⁾, and the industry is realizing how much untapped target space remains⁽⁴⁾, which drives growing need for OmniAb's newer novel-biology platforms



Novel Scaffolds Represent a Broad Market Opportunity

Peptides and single-domain antibodies together address a combined market opportunity of approximately \$1 trillion across bispecifics, CAR-T, radiopharma, and peptide therapeutics⁽⁵⁾, driving need for OmniTides and OmnidAb



Rise of "Lab-in-the-Loop" Discovery

AI-driven discovery increasingly relies on the kind of data that OmniAb's platforms are built to generate, especially important for novel/new targets



Biotech Funding Environment Improving


Rebounding venture and IPO activity, along with a record pace of M&A, expected to help drive more activity across the industry⁽⁶⁾

(1) BIO, Informa Pharma Intelligence, QLS Advisors, Clinical Development Success Rates 2011-2020 | (2) L.E.K. Consulting, "Is Biopharma Doing Enough to Advance Novel Targets?", May 2025 | (3) BioCentury, "Immune-enhancing mechanisms define new oncology targets at AACR", April 2026 (172 new oncology targets identified) | (4) Target 2035 consortium, RSC Medicinal Chemistry, 2022 (fewer than 5% of the human proteome has been successfully drugged) | (5) Combined 2034 TAM across peptide therapeutics (Zion Market Research, \$333B), bispecific antibodies (Towards Healthcare, \$460B), CAR-T cell therapy (Polaris Market Research, \$189B), and radiopharmaceuticals (Precedence Research, \$14B) | (6) BioPharma Dive / PharmaVoice, H1 2026 biotech funding coverage

New Agreements Driven by our New Source Technologies

MAJORITY OF NEW PARTNERSHIPS DRIVEN BY CHICKEN AND NOVEL SCAFFOLD TECHNOLOGIES

Percent of New Partnerships
Driven by Interest in
Novel Chicken-based Source Technologies



- We leverage our vantage point in the industry to drive our innovation investment and technology development decisions
- A majority of new partnerships are driven by interest in our newer technologies

Value Creation with Technology Licenses

A VARIETY OF PATHS TO CREATE VALUE LEVERAGING OUR TECHNOLOGIES



Standard Tech Licensing

Provides access to our suite of discovery source technologies. Deal terms flex partner to partner. **Upfront access fee, clinical milestones, and royalties on approved products.**



Ion Channel Screening

Project-based service and FTE work with milestone and royalty heavy upside, driven by long-term expertise in ion channel drug discovery and screening. **Overall deal size runs significantly larger than our other licensing pathways.**



Entrepreneur Enablement Program

Similar framework as Standard Licensing, but **equity received upfront and as part of the milestones, driving additional potential upside.** Granting novel technology access to early entrepreneurs with promising science.



Asset-Based Deals

We can opportunistically sell technology POC-derived and other program assets, capturing a **large portion of the value upfront** with more modest remaining back-end milestones and royalties.




Transgenic Chicken Advantage

Bill Harriman, Ph.D.

SVP, Discovery Partnership Management & Technology Development

GREATER EVOLUTIONARY DISTANCE YIELDS ROBUST RESPONSES TO HUMAN TARGETS



What is *Biological Intelligence*™



BIOLOGICAL INTELLIGENCE™


We believe that antibodies generated *in vivo* are superior to ones from other sources because they are **naturally optimized** through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles

The ability of the immune system in our engineered transgenic animals to create optimized antibodies for human therapeutics is what we call **BIOLOGICAL INTELLIGENCE**

We believe this approach **increases the efficiency** of therapeutic antibody discovery and may **improve the probability of success** of antibody product candidates in the clinic

OmniAb Transgenic Chickens

ENGINEERED TO PRODUCE HIGH AFFINITY HUMAN BINDING DOMAINS WITH FIT-FOR-PURPOSE STRUCTURAL FEATURES



Single Domain (VHH) Platform: OmnidAb[®]

Traditional approach to generating a therapeutic VHH

Wild-type Llama or Camel

Affinity-matured Camelid VHH



Extensive *ex-vivo* engineering required



Engineered humanized VHH therapeutic candidate



Our Approach

OmnidAb[™] Transgene Design Features

Genetic framework pre-engineered for developability

In vivo affinity maturation and optimization leveraging transgenic chicken host



Developable human sequences can be recovered **directly** from immunized OmnidAb chickens, saving 6 to 12 months on development timeline




Naturally optimized human VHH therapeutic candidate

OmnidAb[™] chickens produce stabilized human sequences and bypass the need for extensive *ex-vivo* engineering

Rapid Progression of OmnidAb Partner Program

KEY MILESTONES FROM TECHNOLOGY LAUNCH TO CLINIC



OmnidAb candidates delivered to partner in less than 7 months to early adopting partner

OmniAb[®]



OmniTides[™]

Yasmina Abdiche, Ph.D.

SVP, Exploratory Research & Advanced Characterization

OmniTides™ Platform

BROADENING THERAPEUTIC PEPTIDE AUDIENCE

Powered by the OmniUltra discovery engine, OmniTides extends to high-value adjacent markets generating optimized therapeutic peptide libraries within a brand tailored to peptide discovery audiences

Antibody Discovery Market



Ultralong applications are understood by target audience and current partner set in the antibody discovery space

Peptide Discovery Market



An integrated **discovery-to-synthesis peptide workflow**, supported by qualified CROs, to deliver therapeutic candidates

OmniTides vs. Other Peptide Discovery Methods

OmniTides Platform

- **Front-loaded novel discovery optimization:** Powerful natural immune mechanisms generate target-specific biologically-enriched peptide libraries, reducing the need for extensive downstream optimization
- **Custom libraries with high functional diversity:** Natural immune diversification produces bespoke libraries with a broad range of functional peptides
- **Built-in stability:** Peptides evolve on a universal scaffold that supports stability and is compatible with downstream chemical synthesis/manufacturing
- **Workflow flexibility:** Amenable to single B-cell discovery, display technologies, and rational-design approaches




Other Methods

- **Combinatorial chemistry and display selection:** Screens large, predefined libraries and often requires substantial downstream optimization to improve activity and developability
- **Rational design:** Uses structural, functional, and computational knowledge to optimize a limited set of candidates, but it may miss novel binders outside of design assumptions

Naturally-optimized peptide libraries powered by the immune system and compatible with chemical synthesis

OmniTides Workflow

NATURALLY-OPTIMIZED PEPTIDE LIBRARIES AMENABLE TO CHEMICAL SYNTHESIS




A novel discovery-to-synthesis workflow, powered by our OmniUltra *in vivo* discovery engine to generate naturally-optimized peptide libraries

Qualified Peptide Manufacturers

OMNITIDE™ PEPTIDE CHEMICAL SYNTHESIS

OmniTides™



Multiple peptide producers positioned for our discovery partners, with expected high purity (retaining full binding affinities to their specific targets) and efficient timelines




Peptide Landscape

Brian McGuinness


Senior Director, Business Development

Peptides Are a Growing Class of Therapeutics




(1) Peptide Therapeutics Market Size, Share, Growth and Trends 2034 – Zion Market Research
*www.peptidejournal.org/reference/fda-approved-peptide-drug-list

Peptides Impacting a Broad Range of High Value/ High Unmet Need Therapeutic Areas



Peptides Are Highly Versatile Therapeutic Modalities

BROAD SCOPE OF APPLICATIONS



Therapeutic peptides make up a **significant proportion** of currently approved peptide drugs

Growing interest in peptide-drug conjugates and targeted peptide-based delivery

Significant strategic upside for platforms that solve delivery problems


OmniTides Platform

EXPANDING PARTNER BASE

OmniTides peptides are **highly versatile modular targeting agents**

Potential to address unmet need in markets with combined **predicted value ~\$1T⁽¹⁾**

(1) Sources: Zion Market Research, Towards Healthcare, Nova One, Roots Analysis



OmniAb[®]



xPloration[®] Platform

Amechi Nwachuku
COO

Bringing xPloration to More Researchers



xPloration[®]



Partner Access Program

- Launched May of 2025
- Available to 100+ partners
- Consistently positive feedback from Partner Access Program users including Big Pharma, global CROs, and specialty biotech
- Live demos are now converting interest into placements

General Availability

- Starting October 2026
- Available to all customers
- Access to xPloration instrument, proprietary consumables, software, and support
- A growing qualified sales pipeline and market research support opening access beyond the partner program

Novel Technology for B Cell Screening

FOR ANTIBODY DISCOVERY TEAMS

xPloration®

Explore boldly. Screen without limits.

Goes from dissociated sample to sorted hits in 1.5 to 4 hours

Customers can run more discovery campaigns each year and reach a candidate sooner







A proprietary
1.5-million-microcapillary
array



Simple, rapid loading
of B cells and reagents
in under 5 minutes



AI-driven deep parallel
functional screening
identifies positive hits




Get deeper insights
on day one

Recover thousands of hits
in under 90 minutes, typically

xPloration Core Application in B Cell Screening

TOTAL ADDRESSABLE MARKET



- Core B Cell Screening is a large and attractive market growing at double digit rates
- While Industry is the majority of the market, Academia is significant and will also remain a focus
- Competition is a mix of specialty and generalized instruments
- Potential expansion applications include:
 - Broader antibody repertoire screening
 - Protein repertoire screening
 - Organism screening

Primary Market Research And Partner Experiences

xPloration Value Drivers:



Higher Throughput⁽¹⁾

Easier to Use

More Robust

Lower Cost

xPloration competes favorably with current methods

(1) Cyto-Mine® / Beacon® platforms, screening up to 80,000 single cells. Cyto-Mine® Chroma | Fully-automated single cell analysis platform, Optofluidic Product Suite - Bruker Cellular Analysis

Insights From Recent Primary Market Research

RESEARCH PERFORMED BY PERCEPTA ASSOCIATES



Commissioned studies included over 200 practitioners in industry and academia

Market Assessment Study

- Quantitative Market Analysis
- Market Dynamics and Sizing
- Competitive Landscape Assessment
- Projected Plans for New Equipment


Conjoint Preference Analysis

- Customer Needs Assessment
- Product Configuration Modeling
- Competitive Landscape Evaluation
- Customer Valuation of Attributes

Active Market for *in vivo* B Cell Screening Technology

PROJECTED TURNOVER RATE


Projected Need for New Screening Platform in Next 3 Years
Percent of Responses



- Almost two thirds of the market should be “*in play*” in the next 3 years
 - Over 20% project needing a new platform in the next 12 months
 - 55% anticipate investing in advanced *in vivo* screening

xPloration Platform Competes Favorably

SUMMARY OF RESULTS FROM CONJOINT MARKET ANALYSIS




- Cells per screen, time per screen, and automation availability to potentially compete as best-in-class
- Cost per screen and cost per hit compete favorably with existing technologies
- xPloration is distinctive on ease-of-use operability dimensions

xPloration offers highly favorable combination of economics, productivity, and operability

(1) Aggregation of importance of attributes when selecting technology, totaling 100%

Most Customers Would Likely Purchase xPloration

WINNING CONCEPTS IN CONJOINT STUDY



- Over 80% intend to purchase the winning xPloration concept across customer types
- Purchase intent linked to delivering on productivity and operability at the right price point

(1) Percent of respondents that would "probably" or "definitely" buy the winning concept

xPloration is a Complete Platform

MULTIPLE REVENUE STREAMS




Instruments

Capital sale of the xPloration system

Anchors the customer relationship and install base

Drives downstream recurring revenue




Consumables

Proprietary chips and kits used each run

Recurring, usage-based revenue that scales with adoption

High margin



Software

Analysis and data management subscriptions

Expands value as workflows and applications grow

Annual license renewals create predictable ARR



Service

Installation, training, and preventive maintenance

Supports uptime, retention, and repeat purchases

Multi-year service contracts on install base

xPloration Positioned to Deliver Durable Revenue Streams


RECURRING REVENUE TO BECOME A LONG-TERM GROWTH DRIVER

in millions


Expected xPloration Revenue

xPloration revenue is expected to double in 2027 and to double again in 2028

\$2 to \$3M



Illustrative Potential xPloration Revenue Mix



We Welcome You to See xPloration in Action

PLEASE JOIN TOUR FOLLOWING Q&A







Enhancing Discovery with AI

Bob Chen, Ph.D.
SVP, Discovery Systems


The Combined Power of BI and AI

THE BIOLOGICAL INTELLIGENCE OF OUR TRANSGENIC ANIMALS COMBINED WITH AI TOOLS
CREATE, SCREEN AND DELIVER THE RIGHT ANTIBODY



In silico Tools to Better Mine Immune Repertoires

OMNIDEEP® AI-POWERED PLATFORM



Expanding xPloration Platform with New Capabilities

Vision

Conversation becoming lab interface
Simplified way to operate instruments

Build

Control software for lab-in-the-loop
Foundation for future autonomous labs

Scientific direction

Scientist input, with future
lab-agent integration

AI layer

Interprets the instruction and
directs workflow

xPloration

Executes screen and recovers
selected cells

ANNOUNCEMENT

Antibody Engineering & Therapeutics Conference

December 2026

Robust Hardware Architecture is Essential for AI Control

xPloration's robust engineering architecture:



No fluidics

Eliminates clogs, leaks, bubbles

Validated components

Supports low maintenance operations

Fast cycle time

Improves cell health and biological results

Right technology at the right moment, as we enter a time when the industry embraces the value of lab automation and instrumentation for big data generation and AI-aided discovery




Finance / Wrap Up


Kurt Gustafson
CFO

OmniAb's Scalable Business Model

Cash R&D and G&A Expense⁽¹⁾



Active Partners & Active Programs⁽²⁾




We focus our work on scalable and leverageable technologies

Active Partners and Active Programs have been growing while Cash R&D and G&A expenses have been decreasing

(1) Cash R&D and G&A Expense = GAAP R&D and G&A Expense less stock-based compensation and depreciation.

(2) See our SEC filings for Active Partners and Active Programs definition. Values shown net of attrition.

The Value of Aggregating Royalties






xPloration revenue streams are additive to this, with consumables having durable and recurring elements similar to royalties

Strong Financial Performance

REAFFIRMING 2026 GUIDANCE

in millions



(1) Cash Costs and Operating Expense = GAAP Costs and Operating Expense less stock-based compensation, depreciation and amortization of intangibles. Refer to OmniAb's Q2 2026 Earnings Release for GAAP to non-GAAP reconciliation.

Upcoming Events

Investor Events and Conferences

Q3 2026 Earnings

October 30

Stifel, New York

November 11

Truist, New York

November 12

Jefferies, London

November 16 – 18

Craig Hallum, New York

November 17

Scientific Conferences and Presentations

EANM Congress, Vienna

October 17 – 21

TIDES Europe, Amsterdam

November 3 – 5

PEGS Summit Europe, Lisbon

November 16 – 18

Antibody Engineering & Therapeutics, San Diego

December 14 – 16



For more information, please visit www.omniab.com